Compare Dell Technologies Inc (DELL) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Medpace Holdings Inc — how do they compare? Dell Technologies Inc trades at $585.9 (market cap $365.31B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Dell Technologies Inc is far larger — about 21.7× Medpace Holdings Inc's market cap, and Dell Technologies Inc pays a 0.44% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Medpace Holdings Inc for 14 Days on average.
| DELL | MEDP | |
|---|---|---|
Market Cap | $365.31B | $16.82B |
Volume | 5,121,365 | 223,093 |
Sector | Technology | Health |
52-Week High | $588.67 | $630.19 |
52-Week Low | $111.10 | $393.42 |
Typical Hold Time | 57 Days | 14 Days |
Enterprise Value | $388.20B | $16.44B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $586.28, up 1.26% today, with a bullish technical outlook as the price hovers near resistance at $585. Recent earnings beats, including Q2 2026 EPS of $7.04 versus $4.91 expected, and a raised AI server revenue forecast to $74 billion for fiscal 2027 highlight strong operational momentum. The stock's valuation reflects growth expectations with a P/E of 33.42 and P/S of 2.52.
The outlook remains positive driven by AI server demand, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is bullish with a $566.35 price target, though the current price exceeds this, suggesting near-term consolidation may precede further gains if execution continues.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
